Pharmacoeconomic review report: Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.) indication, for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product

Buprenorphine extended-release injection (BUP-ER; Sublocade) is indicated for the management of moderate-to-severe opioid use disorder (OUD) in adult patients who have been inducted and clinically stabilized on the equivalent of 8 mg per day to 24 mg per day of transmucosal buprenorphine-containing...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 2019, 2019
Edition:Version: Final
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02891nam a2200349 u 4500
001 EB001897106
003 EBX01000000000000001060111
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200523 r ||| eng
245 0 0 |a Pharmacoeconomic review report: Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.)  |h Elektronische Ressource  |b indication, for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product 
246 3 1 |a CADTH common drug review pharmacoeconomic review report for Sublocade 
246 3 1 |a Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.) 
250 |a Version: Final 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c July 2019, 2019 
300 |a 1 PDF file (33 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Adult 
653 |a Canada 
653 |a Buprenorphine / therapeutic use 
653 |a Opiate Substitution Treatment / economics 
653 |a Cost-Benefit Analysis 
653 |a Methadone / therapeutic use 
653 |a Opioid-Related Disorders / drug therapy 
653 |a Treatment Outcome 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK546358  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 330 
520 |a Buprenorphine extended-release injection (BUP-ER; Sublocade) is indicated for the management of moderate-to-severe opioid use disorder (OUD) in adult patients who have been inducted and clinically stabilized on the equivalent of 8 mg per day to 24 mg per day of transmucosal buprenorphine-containing product in combination with counselling and psychosocial support. BUP-ER is available as 100 mg and 300 mg single-use pre-filled syringe at a submitted price of $550 for either dose. The recommended dosage schedule is 300 mg injection per month for the first two months followed by maintenance on monthly 100 mg injections. The monthly maintenance dose may be increased to 300 mg if the patient does not demonstrate satisfactory response and can tolerate the 100 mg dose, although the 300 mg maintenance dose in clinical trials did not provide additional efficacy compared with the 100 mg dose and was associated with a higher incidence of adverse events and study discontinuations. The manufacturer submitted a cost-utility analysis comparing 100 mg and 300 mg BUP-ER (i.e., 300 mg BUP-ER every four weeks for two doses followed by 100 mg or 300 mg BUP-ER monthly) to oral methadone and generic buprenorphine/naloxone in adults with moderate-to-severe OUD.